Treatment of asthma and airway diseases

• US 5,962,445 A
• Filed: 05/09/1997
• Issued: 10/05/1999
• Est. Priority Date: 05/09/1996
• Status: Expired due to Term

• Current Assignee: Amrad Operations, Pty. Ltd.
• Original Assignee: Amrad Operations, Pty. Ltd.
• Inventors: Stewart, Alastair George
• Primary Examiner(s): Weddington, Kevin E.
• Application Number:
  US08/853,528
• Time in Patent Office: 879 Days
• Field of Search: 514/182, 514/826
• US Class Current: 514/182
• CPC Class Codes: A61K 31/565 not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
• CPC Class Codes: A61K 31/566 having an oxo group in position 17, e.g. estrone
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 11/02 Nasal agents, e.g. decongestants
• CPC Class Codes: A61P 11/06 Antiasthmatics
• CPC Class Codes: A61P 11/08 Bronchodilators

Abstract

The invention relates to use of steroids or steroid analogues in the treatment of chronic and acute inflammation of the airways, particularly asthmatic conditions. It also relates to compounds and compositions which modulate airway remodelling. In a preferred embodiment, the steroid is 2-methoxyoestradiol.

Claims

1. A method of treating a disease characterized by chronic or acute airway inflammation, comprising the step of administering an effective amount of a steroid or steroid analogue selected from the group consisting of 2-methoxyoestradiol, 2-hydroxyoestradiol, 2-methoxyestrone, 2-methoxy-oestradiol-3-methyl ether, and 4 methoxyoestradiol.

2. A method according to claim 1, wherein the steroid is 2-methoxyoestradiol.

3. A method according to claim 2, wherein the disease to be treated is selected from the group consisting of asthma, airway hyperresponsiveness, brochoconstriction, emphysema, pheumonia, atopic disease and pulmonary infection.

4. A method according to claim 1, wherein the disease is asthma.

5. A method according to claim 1, wherein the steroid or steroid analogue is administered in combination with a pharmaceutically acceptable carrier.

6. A method according to claim 1, wherein the steroid or steroid analogue is administered by a route selected from the group consisting of topical, oral and nasal administration.

7. A method according to claim 6, wherein the steroid or steroid analogue is administered by nasal administration.

8. A method according to claim 7, wherein the steroid or steroid analogue is administered by inhalation.

9. A method according to claim 1, wherein the steroid or steroid analogue is administered in a form selected from the group consisting of capsules, cachets, tablets, aerosols, powder granules, micronised particles and solutions.